These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Role of the CD34+ 38- cells in posttransplant hematopoietic recovery. Hénon P; Sovalat H; Bourderont D; Ojeda-Uribe M; Arkam Y; Wunder E; Raidot JP; Husseini F; Audhuy B Stem Cells; 1998; 16 Suppl 1():113-22. PubMed ID: 11012153 [TBL] [Abstract][Full Text] [Related]
27. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991 [TBL] [Abstract][Full Text] [Related]
28. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients. Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956 [TBL] [Abstract][Full Text] [Related]
29. Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF. Delamain MT; Metze K; Marques JF; Reis AR; De Souza CA; Lorand-Metze I Transfus Apher Sci; 2006 Feb; 34(1):33-40. PubMed ID: 16376618 [TBL] [Abstract][Full Text] [Related]
30. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Klaus J; Herrmann D; Breitkreutz I; Hegenbart U; Mazitschek U; Egerer G; Cremer FW; Lowenthal RM; Huesing J; Fruehauf S; Moehler T; Ho AD; Goldschmidt H Eur J Haematol; 2007 Jan; 78(1):21-8. PubMed ID: 17042762 [TBL] [Abstract][Full Text] [Related]
31. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of erythropoietic/hematopoietic reconstitution after BMT by highly fluorescent reticulocyte counts compares favorably with traditional peripheral blood cell counting. Kanold J; Bezou MJ; Coulet M; Quainon F; Malpuech G; Travade P; Deméocq F Bone Marrow Transplant; 1993 Apr; 11(4):313-8. PubMed ID: 7683553 [TBL] [Abstract][Full Text] [Related]
33. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation]. Sawada H; Wake A; Yamasaki Y; Izumi Y Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350 [TBL] [Abstract][Full Text] [Related]
34. Reticulocyte maturation parameters are reliable early predictors of hematopoietic engraftment after allogeneic stem cell transplantation. Molina JR; Sanchez-Garcia J; Torres A; Alvarez MA; Serrano J; Casaño J; Gomez P; Martinez F; Rodriguez A; Martin C Biol Blood Marrow Transplant; 2007 Feb; 13(2):172-82. PubMed ID: 17241923 [TBL] [Abstract][Full Text] [Related]
35. Automated immature reticulocyte counts are early markers of engraftment following autologous PBSC transplantation in patients with lymphoma. George P; Wyre RM; Bruty SJ; Sweetenham JW; Duncombe AS J Hematother Stem Cell Res; 2000 Apr; 9(2):219-23. PubMed ID: 10813535 [TBL] [Abstract][Full Text] [Related]
36. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis. Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930 [TBL] [Abstract][Full Text] [Related]
37. [Clinical observation of selected CD34(+) cell autologous transplantation in non-Hodgin lymphoma: report of 5 cases]. You Y; Xia LH; Zhang C; Liu F; Chen ZC; Zou P Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3127-9. PubMed ID: 18269872 [TBL] [Abstract][Full Text] [Related]
38. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297 [TBL] [Abstract][Full Text] [Related]
39. Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Piccirillo N; Sica S; Laurenti L; Chiusolo P; La Barbera EO; Sorà F; Leone G Bone Marrow Transplant; 1999 Jun; 23(12):1245-50. PubMed ID: 10414910 [TBL] [Abstract][Full Text] [Related]
40. Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2x10(6) CD34+ cells/kg. Abrahamsen JF; Wentzel-Larsen T; Bruserud O Cytotherapy; 2004; 6(4):356-62. PubMed ID: 16146888 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]